Developer docs
API playgroundTry for free, no card

Search company profiles

Cure MITO Foundation

Full company profile

uuid00371c2

Namestring
Cure MITO Foundation
Legal namestring
Cure Mito Foundation
Websiteurl
curemito.org
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMckinney, United States
HQ citystring
Mckinney
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease advocacy, mitochondrial disease research, patient registry services, gene therapy funding, drug repurposing research
Industry3 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Grantmaking Foundations813211
SIC code2 codes
  • Services-Social Services8300
  • Services-Health Services8000
Product category
Rare Disease Patient Advocacy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Donations and Fundraising
TypeGrants Donations
Description

The foundation operates as a 501(c)(3) nonprofit organization (EIN: 82-4665767) primarily funded through individual donations, grassroots fundraising campaigns such as the 'One Shot to Live' SURF1 gene therapy campaign targeting $2.5 million, merchandise sales through Amazon storefront and Bonfire store, and direct charitable contributions.

curemito.org
2Grants and Foundation Funding
TypeGrants Donations
Description

Cure Mito receives grants from institutional funders including the Chan Zuckerberg Initiative (CZI) as a member of the Rare As One Network, RTW Foundation, Rare Village Foundation, and other research foundations supporting rare disease research.

curemito.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Cure Mito Foundation is a patient-led 501(c)(3) nonprofit advocacy organization that accelerates research and treatments for Leigh syndrome and mitochondrial diseases. The foundation funds and supports research projects including gene therapy, drug repurposing, mitochondria transfer, and microbiome studies; operates the world's largest Leigh syndrome patient registry with 400+ participants from 40+ countries; and provides educational resources, family support, and community programs for affected families worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 400+ patients enrolled in global registry from 40+ countries
+4 more records
Product overview1 text field

Cure Mito Foundation operates as a patient-led advocacy organization focused on Leigh syndrome and mitochondrial diseases research. The organization offers a portfolio of interconnected programs including the Leigh Syndrome Global Patient Registry (the world's largest with 400+ participants from 40+ countries), the AboutLeighSyndrome.com educational resource, drug repurposing research initiatives in partnership with Perlara, Prigione Lab, Unravel Biosciences, and Transcripta Bio, and the SURF1 gene therapy development program. Additional offerings include an annual symposium, newsletter, patient support resources including free genetic testing, and merchandise through an Amazon storefront. The organization was founded in 2018 as Cure SURF1 Foundation and rebranded as Cure Mito Foundation in 2021 to expand efforts beyond SURF1 to other causes of Leigh syndrome.

Product and service8 records
1Leigh Syndrome Global Patient Registry
CategoryPatient Registry
Description

The world's largest global patient registry for Leigh syndrome with 400+ participants from 40+ countries. Collects patient data to advance disease understanding, raise awareness for treatments, and connect participants with research and clinical trial opportunities. Registry data is aligned with CDISC regulatory submission standards and integrated into C-Path's RDCA-DAP platform. An AI-powered Registry Assistant was added in 2026.

2SURF1 Gene Therapy Development Program
CategoryResearch Funding Program
Description

Gene replacement therapy development program for SURF1 Leigh syndrome using AAV delivery system. Since 2018, over $1.5 million has been funded toward this program. The therapy aims to deliver a healthy SURF1 gene to cells via intrathecal injection to restore energy production. Partnered with Dr. Steven Gray's lab at UT Southwestern Medical Center.

3Drug Repurposing Research Program
CategoryResearch Funding Program
Description

Multi-pronged drug repurposing initiative spanning yeast-based screening with Perlara PBC, organoid and AI-enabled drug discovery with Prigione Lab, patient RNA-guided drug discovery with Unravel Biosciences (using nasal swabs and AI to create Living Molecular Twins simulations), and patient-derived brain cell drug screening with Transcripta Bio. Cure Mito has invested $225,000 in these projects. Identified losmapimod (FDA Rare Pediatric Disease Designation) and sildenafil (EMA Orphan Drug Designation) as promising candidates.

4Annual Leigh Syndrome Symposium
CategoryCommunity Event Program
Description

Annual virtual conference branded 'Empower and Inspire' that unites families, clinicians, researchers, and industry to drive progress in Leigh syndrome research and community connection. The 2022 conference had 228 participants from 34 countries and it has continued as an annual event through 2025 and beyond.

5Patient Support Resources
CategoryPatient Support Services
Description

Comprehensive support services for Leigh syndrome families including a medical provider directory, free genetic testing partnership with Probably Genetic, family planning guidance, newly diagnosed resources, and a glossary of terms. Targeted at newly diagnosed families and families navigating the disease.

6AboutLeighSyndrome.com
CategoryEducational Resource
Description

First-of-its-kind comprehensive online educational resource dedicated to Leigh syndrome for both patients and physicians, covering education, research, support, and clinical information. Sponsored by PTC Therapeutics.

7Patient Fibroblast Collection
CategoryResearch Biobank Resource
Description

Biospecimen resource created through partnership with Coriell Institute for Medical Research. Skin samples collected from Leigh syndrome patients to create fibroblast cell lines stored at Coriell, enabling researchers worldwide to study the disease through patient-derived cell models.

8Amazon Merchandise Storefront
CategoryFundraising Merchandise
Description

Online storefront selling branded merchandise including shirts, hoodies, and awareness items at amazon.com/shop/curemitofoundation, with proceeds supporting Leigh syndrome research and the foundation's mission.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-07-02
Description

Patient registry collaboration for the 25-35% of patients who have both Leigh syndrome and PDCD, aligning registries on Sanford Health CoRDS platform.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

Corporate Advisory Council (CAC) formed with five prominent rare disease companies to provide strategic guidance and industry expertise to Cure Mito Foundation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-09
Description

Data sharing agreement to incorporate Leigh syndrome patient registry data into C-Path's Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) to accelerate treatment development.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-09-19
Description

Partnership with MitoAction and AllStripes for Leigh syndrome research. AllStripes provides platform to accelerate research for rare disease patients and inform natural history understanding.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cure Mito is a member of the Rare As One Network, supported by a grant from CZI. This partnership provides funding and network support for patient-led rare disease research initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Primary research partner for SURF1 gene therapy development. Dr. Steven Gray's lab at UT Southwestern has received over $1 million in funding from Cure Mito since 2018 to develop gene replacement therapy for SURF1 Leigh syndrome.

Strategic tierCoreTypeTechnology or Integration
Description

Biotechnology partnership for yeast-based drug repurposing screens. Testing thousands of existing drugs in yeast models of Leigh syndrome to identify candidates for clinical studies. Identified losmapimod with FDA Rare Pediatric Disease Designation.

8Prigione Lab (Heinrich Heine University)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration on organoids and AI-enabled drug repurposing. Identified azole compounds and sildenafil as promising candidates; sildenafil received EMA Orphan Drug Designation for MT-ATP6 Leigh syndrome.

curemito.org
Strategic tierCoreTypeTechnology or Integration
Description

Patient RNA-guided drug discovery partnership using nasal swab collection and AI-driven analysis to predict which drugs could help across Leigh syndrome population. Created 'Living Molecular Twins' digital simulations.

Strategic tierMajorTypeTechnology or Integration
Description

Drug screening collaboration in patient-derived brain cells. Screened thousands of FDA-approved drugs in neurons derived from Leigh syndrome patients; identified omaveloxolone as promising candidate.

Strategic tierMajorTypeTechnology or Integration
Description

Patient fibroblast cell lines created and stored at Coriell Institute. Cell models from Leigh syndrome patients stored and shared with researchers for disease study.

12Sanford Research / CoRDS
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leigh Syndrome Global Patient Registry hosted on Sanford Health CoRDS platform, enabling global patient enrollment and data collection for research purposes.

curemito.org
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Biotech partnership to advance SURF1 gene therapy toward clinical trial. SURF1-AAV therapy received FDA Orphan Drug Designation. Partnership included natural history collaboration with AllStripes.

Strategic tierMajorTypeImplementation/ SI/ Consulting Partner
Description

Partnership on alignment and interoperability of Leigh Syndrome Registry Data with Regulatory Submission Standards (CDISC), enabling data use in regulatory submissions.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to increase access to genetic testing within Leigh syndrome community. Probably Genetic provides no-cost genetic testing program including sample collection kits and genetic counseling.

16Dr. Qinglan Ling
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Scientific Advisor and former postdoc in Dr. Gray's lab, now Assistant Professor at UMass Chan Medical School. Received $1 million NIH award for MT-ATP6 research. Led animal experiments for SURF1 gene therapy.

curemito.org
17Brestoff Lab (Washington University)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

$140,000 grant for study determining effects of in vitro mitochondria transplantation in patient-derived fibroblasts.

curemito.org
18Dr. Ibrahim Elsharkawi (Icahn School of Medicine at Mount Sinai)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

$34,000 grant for study investigating the role of gut microbiome in primary mitochondrial disease.

curemito.org
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Foundation for Mitochondrial Disease (FAME)
TypeDirect peer
Description

Patient-led foundation raising funds for mitochondrial disease research and family support, with a similar patient-advocacy-plus-grantmaking model to Cure Mito Foundation.

2Mito Foundation (Australia)
TypeRegional player
Description

Australian patient advocacy and research funding organization for mitochondrial disease, comparable in mission and operating model but serving a separate geography.

TypeEmerging player
Description

Patient-led rare disease nonprofit that funds Duchenne muscular dystrophy research and operates a robust registry, advocacy, and drug-development accelerator model directly analogous to Cure Mito's Leigh syndrome strategy.

TypeBroad incumbent
Description

Advocacy organization advancing policies supporting rare disease patients and therapies. Engages Cure Mito in legislative and regulatory advocacy shared across rare disease patient communities.

5Metabolic Support UK
TypeRegional player
Description

U.K. patient support charity for people affected by inherited metabolic diseases including mitochondrial disorders. Comparable support and advocacy mission in a complementary geography.

6United Mitochondrial Disease Foundation (UMDF)
TypeDirect peer
Description

The largest U.S. nonprofit focused on mitochondrial disease, funding research, supporting patients, and convening the annual Mitochondrial Medicine Symposium. Directly comparable mission and constituency with Cure Mito Foundation.

TypeOthers
Description

Clinical-stage gene therapy company developing AAV-based therapies for CNS diseases, including the original SURF1-AAV (TSHA-104) program partnered with Cure Mito. An ecosystem participant and former co-developer rather than a direct advocacy peer.

TypeBroad incumbent
Description

The largest U.S. umbrella advocacy organization for all rare diseases, providing policy advocacy, research grants, and patient programs. A broader incumbent that Cure Mito engages alongside via the rare-disease ecosystem.

TypeDirect peer
Description

Patient advocacy nonprofit dedicated to mitochondrial disease, operating patient support programs, awareness campaigns, and community resources for patients and families affected by mitochondrial disorders including Leigh syndrome.

TypeRegional player
Description

U.K.-based mitochondrial disease patient charity funding research, providing family support, and convening the mito community. Operates similar programs in a complementary geographic market.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cure MITO Foundation

Rare Disease Patient Advocacycuremito.org

Cure MITO Foundation firmographics

Firmographics
Name
Cure MITO Foundation
Legal name
Cure Mito Foundation
Website
https://curemito.org
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Cure MITO Foundation industry classification

Industry
Product category
Rare Disease Patient Advocacy
NAICS
Voluntary Health Organizations (813212), Grantmaking Foundations (813211)
SIC
Services-Social Services (8300), Services-Health Services (8000)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)

Keywords

  • Rare disease advocacy
  • Mitochondrial disease research
  • Patient registry services
  • Gene therapy funding
  • Drug repurposing research

Where Cure MITO Foundation is headquartered

Location

Headquarters

HQ city
Mckinney
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cure MITO Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Donations and Fundraising: The foundation operates as a 501(c)(3) nonprofit organization (EIN: 82-4665767) primarily funded through individual donations, grassroots fundraising campaigns such as the 'One Shot to Live' SURF1 gene therapy campaign targeting $2.5 million, merchandise sales through Amazon storefront and Bonfire store, and direct charitable contributions.
  2. Grants and Foundation Funding: Cure Mito receives grants from institutional funders including the Chan Zuckerberg Initiative (CZI) as a member of the Rare As One Network, RTW Foundation, Rare Village Foundation, and other research foundations supporting rare disease research.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Cure MITO Foundation product offering

Product offering

Core offering

Cure Mito Foundation is a patient-led 501(c)(3) nonprofit advocacy organization that accelerates research and treatments for Leigh syndrome and mitochondrial diseases. The foundation funds and supports research projects including gene therapy, drug repurposing, mitochondria transfer, and microbiome studies; operates the world's largest Leigh syndrome patient registry with 400+ participants from 40+ countries; and provides educational resources, family support, and community programs for affected families worldwide.

Product overview

Cure Mito Foundation operates as a patient-led advocacy organization focused on Leigh syndrome and mitochondrial diseases research. The organization offers a portfolio of interconnected programs including the Leigh Syndrome Global Patient Registry (the world's largest with 400+ participants from 40+ countries), the AboutLeighSyndrome.com educational resource, drug repurposing research initiatives in partnership with Perlara, Prigione Lab, Unravel Biosciences, and Transcripta Bio, and the SURF1 gene therapy development program. Additional offerings include an annual symposium, newsletter, patient support resources including free genetic testing, and merchandise through an Amazon storefront. The organization was founded in 2018 as Cure SURF1 Foundation and rebranded as Cure Mito Foundation in 2021 to expand efforts beyond SURF1 to other causes of Leigh syndrome.

Differentiator

Problem solved

Functional benefit

Products and services

  • Leigh Syndrome Global Patient Registry The world's largest global patient registry for Leigh syndrome with 400+ participants from 40+ countries. Collects patient data to advance disease understanding, raise awareness for treatments, and connect participants with research and clinical trial opportunities. Registry data is aligned with CDISC regulatory submission standards and integrated into C-Path's RDCA-DAP platform. An AI-powered Registry Assistant was added in 2026.
  • SURF1 Gene Therapy Development Program Gene replacement therapy development program for SURF1 Leigh syndrome using AAV delivery system. Since 2018, over $1.5 million has been funded toward this program. The therapy aims to deliver a healthy SURF1 gene to cells via intrathecal injection to restore energy production. Partnered with Dr. Steven Gray's lab at UT Southwestern Medical Center.
  • Drug Repurposing Research Program Multi-pronged drug repurposing initiative spanning yeast-based screening with Perlara PBC, organoid and AI-enabled drug discovery with Prigione Lab, patient RNA-guided drug discovery with Unravel Biosciences (using nasal swabs and AI to create Living Molecular Twins simulations), and patient-derived brain cell drug screening with Transcripta Bio. Cure Mito has invested $225,000 in these projects. Identified losmapimod (FDA Rare Pediatric Disease Designation) and sildenafil (EMA Orphan Drug Designation) as promising candidates.
  • Annual Leigh Syndrome Symposium Annual virtual conference branded 'Empower and Inspire' that unites families, clinicians, researchers, and industry to drive progress in Leigh syndrome research and community connection. The 2022 conference had 228 participants from 34 countries and it has continued as an annual event through 2025 and beyond.
  • Patient Support Resources Comprehensive support services for Leigh syndrome families including a medical provider directory, free genetic testing partnership with Probably Genetic, family planning guidance, newly diagnosed resources, and a glossary of terms. Targeted at newly diagnosed families and families navigating the disease.
  • AboutLeighSyndrome.com First-of-its-kind comprehensive online educational resource dedicated to Leigh syndrome for both patients and physicians, covering education, research, support, and clinical information. Sponsored by PTC Therapeutics.
  • Patient Fibroblast Collection Biospecimen resource created through partnership with Coriell Institute for Medical Research. Skin samples collected from Leigh syndrome patients to create fibroblast cell lines stored at Coriell, enabling researchers worldwide to study the disease through patient-derived cell models.
  • Amazon Merchandise Storefront Online storefront selling branded merchandise including shirts, hoodies, and awareness items at amazon.com/shop/curemitofoundation, with proceeds supporting Leigh syndrome research and the foundation's mission.

Quantifiable outcome

  • 400+ patients enrolled in global registry from 40+ countries
  • +4 more outcomes

Companies that use Cure MITO Foundation

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Cure MITO Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Cure MITO Foundation partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered minor, major and core.

  • Hope for PDCD FoundationminorStrategic or Co-development Partner · 2 July 2024Patient registry collaboration for the 25-35% of patients who have both Leigh syndrome and PDCD, aligning registries on Sanford Health CoRDS platform.
  • PTC Therapeutics, Astellas Pharma US, Saol Therapeutics, Standigm, Abliva ABmajorStrategic or Co-development Partner · 1 July 2024Corporate Advisory Council (CAC) formed with five prominent rare disease companies to provide strategic guidance and industry expertise to Cure Mito Foundation.
  • Critical Path Institute (C-Path)coreStrategic or Co-development Partner · 9 November 2021Data sharing agreement to incorporate Leigh syndrome patient registry data into C-Path's Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) to accelerate treatment development.
  • AllStripesmajorStrategic or Co-development Partner · 19 September 2020Partnership with MitoAction and AllStripes for Leigh syndrome research. AllStripes provides platform to accelerate research for rare disease patients and inform natural history understanding.
  • Chan Zuckerberg Initiative (CZI)coreStrategic or Co-development PartnerCure Mito is a member of the Rare As One Network, supported by a grant from CZI. This partnership provides funding and network support for patient-led rare disease research initiatives.
  • UT Southwestern Medical CentercoreStrategic or Co-development PartnerPrimary research partner for SURF1 gene therapy development. Dr. Steven Gray's lab at UT Southwestern has received over $1 million in funding from Cure Mito since 2018 to develop gene replacement therapy for SURF1 Leigh syndrome.
  • Perlara PBCcoreTechnology or IntegrationBiotechnology partnership for yeast-based drug repurposing screens. Testing thousands of existing drugs in yeast models of Leigh syndrome to identify candidates for clinical studies. Identified losmapimod with FDA Rare Pediatric Disease Designation.
  • Prigione Lab (Heinrich Heine University)coreStrategic or Co-development PartnerResearch collaboration on organoids and AI-enabled drug repurposing. Identified azole compounds and sildenafil as promising candidates; sildenafil received EMA Orphan Drug Designation for MT-ATP6 Leigh syndrome.
  • Unravel BiosciencescoreTechnology or IntegrationPatient RNA-guided drug discovery partnership using nasal swab collection and AI-driven analysis to predict which drugs could help across Leigh syndrome population. Created 'Living Molecular Twins' digital simulations.
  • Transcripta BiomajorTechnology or IntegrationDrug screening collaboration in patient-derived brain cells. Screened thousands of FDA-approved drugs in neurons derived from Leigh syndrome patients; identified omaveloxolone as promising candidate.
  • Coriell Institute for Medical ResearchmajorTechnology or IntegrationPatient fibroblast cell lines created and stored at Coriell Institute. Cell models from Leigh syndrome patients stored and shared with researchers for disease study.
  • Sanford Research / CoRDScoreStrategic or Co-development PartnerLeigh Syndrome Global Patient Registry hosted on Sanford Health CoRDS platform, enabling global patient enrollment and data collection for research purposes.
  • Taysha Gene TherapiesmajorStrategic or Co-development PartnerBiotech partnership to advance SURF1 gene therapy toward clinical trial. SURF1-AAV therapy received FDA Orphan Drug Designation. Partnership included natural history collaboration with AllStripes.
  • Sumptuous Data SciencesmajorImplementation/ SI/ Consulting PartnerPartnership on alignment and interoperability of Leigh Syndrome Registry Data with Regulatory Submission Standards (CDISC), enabling data use in regulatory submissions.
  • Probably GeneticminorChannel Partner/ Reseller/ DistributorPartnership to increase access to genetic testing within Leigh syndrome community. Probably Genetic provides no-cost genetic testing program including sample collection kits and genetic counseling.
  • Dr. Qinglan LingcoreStrategic or Co-development PartnerScientific Advisor and former postdoc in Dr. Gray's lab, now Assistant Professor at UMass Chan Medical School. Received $1 million NIH award for MT-ATP6 research. Led animal experiments for SURF1 gene therapy.
  • Brestoff Lab (Washington University)majorStrategic or Co-development Partner$140,000 grant for study determining effects of in vitro mitochondria transplantation in patient-derived fibroblasts.
  • Dr. Ibrahim Elsharkawi (Icahn School of Medicine at Mount Sinai)majorStrategic or Co-development Partner$34,000 grant for study investigating the role of gut microbiome in primary mitochondrial disease.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Cure MITO Foundation competitors and assessment

Company assessment

Direct peers

  • Foundation for Mitochondrial Disease (FAME): Patient-led foundation raising funds for mitochondrial disease research and family support, with a similar patient-advocacy-plus-grantmaking model to Cure Mito Foundation.
  • United Mitochondrial Disease Foundation (UMDF): The largest U.S. nonprofit focused on mitochondrial disease, funding research, supporting patients, and convening the annual Mitochondrial Medicine Symposium. Directly comparable mission and constituency with Cure Mito Foundation.
  • MitoAction: Patient advocacy nonprofit dedicated to mitochondrial disease, operating patient support programs, awareness campaigns, and community resources for patients and families affected by mitochondrial disorders including Leigh syndrome.

Regional players

  • Mito Foundation (Australia): Australian patient advocacy and research funding organization for mitochondrial disease, comparable in mission and operating model but serving a separate geography.
  • Metabolic Support UK: U.K. patient support charity for people affected by inherited metabolic diseases including mitochondrial disorders. Comparable support and advocacy mission in a complementary geography.
  • The Lily Foundation: U.K.-based mitochondrial disease patient charity funding research, providing family support, and convening the mito community. Operates similar programs in a complementary geographic market.

Emerging players

  • Parent Project Muscular Dystrophy (PPMD): Patient-led rare disease nonprofit that funds Duchenne muscular dystrophy research and operates a robust registry, advocacy, and drug-development accelerator model directly analogous to Cure Mito's Leigh syndrome strategy.

Broad incumbents

  • EveryLife Foundation for Rare Diseases: Advocacy organization advancing policies supporting rare disease patients and therapies. Engages Cure Mito in legislative and regulatory advocacy shared across rare disease patient communities.
  • National Organization for Rare Disorders (NORD): The largest U.S. umbrella advocacy organization for all rare diseases, providing policy advocacy, research grants, and patient programs. A broader incumbent that Cure Mito engages alongside via the rare-disease ecosystem.

Others

  • Taysha Gene Therapies: Clinical-stage gene therapy company developing AAV-based therapies for CNS diseases, including the original SURF1-AAV (TSHA-104) program partnered with Cure Mito. An ecosystem participant and former co-developer rather than a direct advocacy peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Cure MITO Foundation social profiles

Digital presence

Cure MITO Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cure MITO Foundation leadership team

Management profile

Number of profiles

Profiles3 records

Cure MITO Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cure MITO Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cure MITO Foundation

What does Cure MITO Foundation do?

Cure Mito Foundation is a patient-led 501(c)(3) nonprofit advocacy organization that accelerates research and treatments for Leigh syndrome and mitochondrial diseases. The foundation funds and supports research projects including gene therapy, drug repurposing, mitochondria transfer, and microbiome studies; operates the world's largest Leigh syndrome patient registry with 400+ participants from 40+ countries; and provides educational resources, family support, and community programs for affected families worldwide.

Is Cure MITO Foundation a public or private company?

Cure MITO Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Cure MITO Foundation founded?

Cure MITO Foundation was founded in 2018. It employs 1 to 10 people.

Where is Cure MITO Foundation based?

Cure MITO Foundation is headquartered in Mckinney, United States, in the North America region.

How does Cure MITO Foundation make money?

Two revenue lines are on record. Donations and Fundraising is the primary driver. The others are grants and Foundation Funding.

Who are Cure MITO Foundation's main competitors?

Direct peers on record are Foundation for Mitochondrial Disease (FAME), United Mitochondrial Disease Foundation (UMDF) and MitoAction. Regional players are Mito Foundation (Australia), Metabolic Support UK and The Lily Foundation. Parent Project Muscular Dystrophy (PPMD) is listed as an emerging player. Broad incumbents are EveryLife Foundation for Rare Diseases and National Organization for Rare Disorders (NORD). Taysha Gene Therapies is listed as an others.

Does Cure MITO Foundation have an API?

No public API is recorded for Cure MITO Foundation.

What industry is Cure MITO Foundation in?

Cure MITO Foundation's product category is Rare Disease Patient Advocacy. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales